Mondelez International, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Mondelez International, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.54B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $36.44B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $36.02B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $31.50B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $28.72B | Feb 2, 2024 |
| FY2020 | Dec 31, 2020 | $7.30B | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $6.67B | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $5.91B | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $6.71B | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $6.91B | Feb 5, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.94B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $14.26B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $13.76B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $11.31B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $11.25B | Feb 2, 2024 |
| FY2020 | Dec 31, 2020 | $2.87B | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $2.79B | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $2.33B | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $2.45B | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $2.76B | Feb 5, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.45B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.61B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.96B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $2.72B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $4.30B | Feb 2, 2024 |
| FY2020 | Dec 31, 2020 | $1.16B | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $1.12B | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $544.00M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $736.00M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $733.00M | Feb 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.55B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $6.35B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $5.50B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $3.53B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $4.65B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $3.85B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $3.84B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $3.31B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $3.46B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $2.55B | Feb 8, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $400.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $380.00M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $346.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $347.00M | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $332.00M | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $351.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $362.00M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $366.00M | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $376.00M | Feb 8, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.17B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $7.44B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $8.00B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $7.38B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $6.26B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $6.10B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $6.14B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $6.48B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $5.94B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $6.55B | Feb 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.51B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.91B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.71B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $3.91B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $4.14B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $3.96B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $3.97B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $3.95B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $2.59B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $2.84B | Feb 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.28B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $1.11B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $906.00M | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $965.00M | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $863.00M | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $925.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $1.10B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.01B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $1.22B | Feb 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.49B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $68.50B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $71.39B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $71.16B | Feb 2, 2024 |
| FY2023 | Dec 31, 2021 | $67.09B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $67.81B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $64.52B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $62.62B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $62.96B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $61.51B | Feb 8, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.60B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $41.54B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $43.03B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $44.24B | Feb 2, 2024 |
| FY2022 | Dec 31, 2021 | $38.77B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $40.16B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $37.20B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $37.02B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $36.88B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $36.32B | Feb 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.84B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $26.93B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $28.33B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $26.88B | Feb 2, 2024 |
| FY2022 | Dec 31, 2021 | $28.27B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $27.58B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $27.24B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $25.64B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $25.99B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $25.16B | Feb 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.34B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $23.02B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $23.90B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $23.45B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $21.98B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $21.90B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $20.85B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $20.73B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $21.09B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $20.28B | Feb 8, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.41B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $36.48B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $34.24B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $31.48B | Feb 2, 2024 |
| FY2022 | Dec 31, 2021 | $30.81B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $28.40B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $26.62B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $24.49B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $22.63B | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $21.15B | Feb 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $4.48B | Feb 25, 2013 |
| FY2011 | Dec 31, 2011 | $1.97B | Feb 27, 2012 |
| FY2010 | Dec 31, 2010 | $2.48B | Feb 28, 2011 |
| FY2009 | Dec 31, 2009 | $2.10B | Feb 25, 2010 |
| FY2009 | Dec 31, 2008 | $1.24B | Feb 25, 2010 |
| FY2009 | Dec 31, 2007 | $567.00M | Feb 25, 2010 |
| FY2009 | Dec 31, 2006 | $239.00M | Feb 25, 2010 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $15.88B | Feb 7, 2020 |
| FY2018 | Dec 31, 2018 | $15.25B | Feb 8, 2019 |
| FY2017 | Dec 31, 2017 | $14.20B | Feb 9, 2018 |
| FY2016 | Dec 31, 2016 | $14.74B | Feb 24, 2017 |
| FY2015 | Dec 31, 2015 | $15.23B | Feb 19, 2016 |
| FY2014 | Dec 31, 2014 | $15.41B | Feb 20, 2015 |
| FY2013 | Dec 31, 2013 | $15.51B | Mar 3, 2014 |
| FY2012 | Dec 31, 2012 | $19.16B | Feb 25, 2013 |
| FY2011 | Dec 31, 2011 | $26.75B | Feb 27, 2012 |
| FY2011 | Dec 31, 2010 | $27.97B | Feb 27, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 2, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 5, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 3 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 2, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 5, 2021 |